Poly Medicure (NSE:POLYMED) Research & Development: ₹272 Mil (TTM As of Mar. 2026)


NSE:POLYMED Poly Medicure Ltd NSE:POLYMED
90 GF Score
Price ₹1,666.10
GF Value ₹2,299.45
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Poly Medicure Research & Development?

Poly Medicure NSE:POLYMED -1.26% 90 Research & Development is ₹272 Mil as of Mar. 2026. GuruFocus rates NSE:POLYMED with a GF Score™ of 90/100 and a GF Value™ of ₹2,299.45 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Poly Medicure's Research & Development for the three months ended in Mar. 2026 was ₹67 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹272 Mil.

Poly Medicure  (NSE:POLYMED) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Poly Medicure Research & Development Related Terms

Poly Medicure Research & Development Historical Data

* Premium members only.

The historical data trend for Poly Medicure's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poly Medicure Research & Development Chart

Poly Medicure Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 187.71 178.03 194.42 240.25 298.76

Poly Medicure Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.77 66.81 78.07 59.58 67.43
NSE:POLYMED
90GF Score
Poly Medicure Ltd NSE:POLYMED
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Poly Medicure Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹272 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹272 Mil mean?
Poly Medicure (NSE:POLYMED) has a Research & Development of ₹272 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Poly Medicure and its competitors.
Is Poly Medicure's Research & Development too high?
Poly Medicure's current Research & Development is ₹272 Mil. Overall, Poly Medicure has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Poly Medicure's Research & Development compare to ISRG and BDX?
Poly Medicure's Research & Development of ₹272 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Poly Medicure and its competitors. Poly Medicure's current Research & Development is ₹272 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poly Medicure stock overvalued right now?
Based on GuruFocus' analysis, Poly Medicure (NSE:POLYMED) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,299.45, compared to a current price of ₹1,666.10 — trading 27.5% below its estimated fair value. The current Research & Development is ₹272 Mil. Poly Medicure's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Poly Medicure (NSE:POLYMED), the current Research & Development is ₹272 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Poly Medicure (NSE:POLYMED) Overvalued in 2026?

Based on GuruFocus' analysis, Poly Medicure stock appears to be undervalued. The current stock price of ₹1,666.10 is trading 27.5% below its estimated GF Value™ of ₹2,299.45. GuruFocus considers Poly Medicure to be Modestly Undervalued.

Key valuation signals for NSE:POLYMED:

  • Research & Development: ₹272 Mil
  • GF Value™: ₹2,299.45 vs. price of ₹1,666.10 (27.5% below fair value)
  • GF Score™: 90/100 with 6 warning signs

No single metric tells the full story. See the NSE:POLYMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Poly Medicure Business Description

Other Exchanges 531768:India
Address Okhla Industrial Estate, 232-B, 3rd Floor, Phase III, New Delhi, IND, 110020
Poly Medicure Ltd engages in the manufacturing and sale of medical devices. It offers disposable medical devices for infusion therapy, blood management, gastroenterology, vascular access, surgery and wound drainage, anesthesia, and urology. Some of its products include Ventilator Circuit Combo Kits, Bain Circuits, Safety Introducer Needles, High-Pressure Vaccum Bottle-Triplet, Catheters, and others. Geographically, it derives a majority of its revenue from exports. The company operates under one segment namely Medical Devices.
90GF Score

Get the complete analysis for NSE:POLYMED

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,666.10
Price
₹2,299.45
GF Value